

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO	). I	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/749,075	-	12/30/2003	Clark A. Briggs	6017.US.D2	7952
23492	7590	01/12/2006		EXAMINER	
	DEBERA LABORAT		ULM, JO	ULM, JOHN D	
	OTT PARK		ART UNIT	PAPER NUMBER	
DEPT. 37	7/AP6A		1649	<u>.</u>	
ABBOTT	PARK, IL	60064-6008	DATE MAILED: 01/12/2006		

Please find below and/or attached an Office communication concerning this application or proceeding.

		Apı	olication No.	Applicant(s)	Applicant(s)			
Office Action Summary			749,075	BRIGGS ET AL.	BRIGGS ET AL.			
			aminer	Art Unit				
			n D. Ulm	1649				
Period fo	The MAILING DATE of this communic or Reply	ation appears	on the cover sheet	with the correspondence ac	ddress			
WHIC - External after - If NC - Failu Any	ORTENED STATUTORY PERIOD FO CHEVER IS LONGER, FROM THE MA nsions of time may be available under the provisions of SIX (6) MONTHS from the mailing date of this community or to reply is specified above, the maximum stature to reply within the set or extended period for reply we reply received by the Office later than three months after the patent term adjustment. See 37 CFR 1.704(b).	ILING DATE 37 CFR 1.136(a). nication. ttory period will app ill, by statute, cause	OF THIS COMMUN In no event, however, may a ly and will expire SIX (6) MO the application to become a	IICATION. a reply be timely filed  DNTHS from the mailing date of this of ABANDONED (35 U.S.C. § 133).				
Status								
1)	Responsive to communication(s) filed	on						
2a)□			on is non-final.					
	,—							
,_	closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.							
Dispositi	on of Claims							
4)⊠	Claim(s) 1-51 is/are pending in the ap	plication.						
	4a) Of the above claim(s) is/are withdrawn from consideration.							
	☐ Claim(s) is/are allowed.							
6)□	Claim(s) is/are rejected.							
7)	Claim(s) is/are objected to.							
8)⊠	Claim(s) <u>1-51</u> are subject to restriction	n and/or electi	on requirement.					
Applicati	on Papers							
9)□	The specification is objected to by the	Examiner.						
10)	The drawing(s) filed on is/are:	a) accepted	d or b)□ objected to	by the Examiner.				
	Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).							
	Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).							
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.								
Priority ι	ınder 35 U.S.C. § 119							
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of:								
	1. Certified copies of the priority documents have been received.							
	2. Certified copies of the priority documents have been received in Application No							
	3. Copies of the certified copies of the priority documents have been received in this National Stage							
	application from the International Bureau (PCT Rule 17.2(a)).							
* 8	See the attached detailed Office action	for a list of the	e certified copies no	it received.				
Attachmen	•		<b>∧</b> □	. S				
	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO	<b>D-948</b> )		Summary (PTO-413) o(s)/Mail Date				
3) 🔲 Inforr	nation Disclosure Statement(s) (PTO-1449 or P r No(s)/Mail Date			Informal Patent Application (PT	O-152)			

Application/Control Number: 10/749,075

Art Unit: 1649

Claims 1 to 51 are pending in the instant application. The amendment to the claims that was filed on 16 August of 2004 has not been entered because it does not comply with 37 C.F.R. 1.121.

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- Claims 1 to 20, 45 and 46, drawn to a polynucleotide encoding a receptor subunit, a vector and host cell containing that polynucleotide, and method of use, classified in class 435, subclass 69.1.
- Claims 22, 23 and 47 to 49, drawn to a receptor subunit polypeptide, classified in class 530, subclass 350.
- III. Claims 23 to 38, drawn to a receptor specific assay, classified in class 435, subclass 7.21.
- IV. Claims 39 to 41, drawn to a compound of unspecified constitution and method of use, classification undeterminable.
- V. Claims 42 to 44, drawn to a method of detecting a specific polynucleotide
   in a sample, classified in class 435, subclass 6.
- VI. Claims 50 and 51, drawn to an antibody and method of use, classified in class 530, subclass 388.22.

The inventions are distinct, each from the other because of the following reasons:

The polynucleotide of invention I, the polypeptide of invention II, the compound of invention IV and the antibody of invention are five materially different chemical compounds each of which can be made and used without the others. These five different compounds to not reflect a common inventive concept because they do not

Application/Control Number: 10/749,075

Art Unit: 1649

share a common feature or combination of features that distinguishes them as a group from the prior art.

A host cell of invention I and a polypeptide of invention II are each related to invention III as process of making and process of using the product. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the process as claimed can be practiced with more than one materially different product

The process of invention V is unrelated to any of the claimed products.

Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the claimed process neither makes nor uses any one or more of the claimed products.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification, restriction for examination purposes as indicated is proper.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one

Art Unit: 1649

or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to John D. Ulm whose telephone number is (571) 272-0880. The examiner can normally be reached on 9:00AM to 5:30PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Janet Andres can be reached on (571) 272-0867. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

JOHN ULM PRINARY EXAMINER CROUP 1800